Compare, Analyse NEULAND LABS with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NEULAND LABS vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NEULAND LABS   ACTAVIS
EQUITY SHARE DATA
    NEULAND LABS
Mar-20
ACTAVIS
Dec-18
NEULAND LABS/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs75414,247-   
Low Rs2479,557-   
Sales per share (Unadj.) Rs594.53,494.9-  
Earnings per share (Unadj.) Rs12.6-1,125.7-  
Cash flow per share (Unadj.) Rs37.0368.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs553.414,414.7-  
Shares outstanding (eoy) m12.83332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.83.4 24.7%   
Avg P/E ratio x39.6-10.6 -374.7%  
P/CF ratio (eoy) x13.532.3 41.8%  
Price / Book Value ratio x0.90.8 109.5%  
Dividend payout %15.80-   
Avg Mkt Cap Rs m6,4213,958,701 0.2%   
No. of employees `0001.316.9 7.6%   
Total wages/salary Rs m1,2360-   
Avg. sales/employee Rs Th5,949.468,780.9 8.6%   
Avg. wages/employee Rs Th963.80-   
Avg. net profit/employee Rs Th126.4-22,154.4 -0.6%   
INCOME DATA
Net Sales Rs m7,6271,162,397 0.7%  
Other income Rs m3922,229 0.2%   
Total revenues Rs m7,6661,184,626 0.6%   
Gross profit Rs m1,01930,461 3.3%  
Depreciation Rs m313496,899 0.1%   
Interest Rs m21667,077 0.3%   
Profit before tax Rs m529-511,287 -0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0130,399 0.0%   
Tax Rs m367-6,479 -5.7%   
Profit after tax Rs m162-374,409 -0.0%  
Gross profit margin %13.42.6 509.8%  
Effective tax rate %69.41.3 5,474.1%   
Net profit margin %2.1-32.2 -6.6%  
BALANCE SHEET DATA
Current assets Rs m5,152476,754 1.1%   
Current liabilities Rs m3,576421,753 0.8%   
Net working cap to sales %20.74.7 436.6%  
Current ratio x1.41.1 127.4%  
Inventory Days Days10520 536.5%  
Debtors Days Days9166 137.0%  
Net fixed assets Rs m3,969131,577 3.0%   
Share capital Rs m1290-   
"Free" reserves Rs m6,9710-   
Net worth Rs m7,1004,794,344 0.1%   
Long term debt Rs m7741,688,262 0.0%   
Total assets Rs m12,3107,494,650 0.2%  
Interest coverage x3.5-6.6 -52.1%   
Debt to equity ratio x0.10.4 30.9%  
Sales to assets ratio x0.60.2 399.5%   
Return on assets %3.1-4.1 -74.8%  
Return on equity %2.3-7.8 -29.2%  
Return on capital %9.5-4.8 -195.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m3,5940-   
CASH FLOW
From Operations Rs m573415,281 0.1%  
From Investments Rs m-487228,143 -0.2%  
From Financial Activity Rs m-55-712,746 0.0%  
Net Cashflow Rs m33-68,977 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.63 Rs / USD

Compare NEULAND LABS With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NEULAND LABS With: SHASUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  PANACEA BIOTECH  TTK HEALTHCARE  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views On News

NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)

Feb 3, 2021 | Updated on Feb 3, 2021

For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.

NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)

Sep 2, 2020 | Updated on Sep 2, 2020

Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

More Views on News

Most Popular

Time to Buy Smallcaps? (Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners (Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away? (Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her? (Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

NEULAND LABS SHARE PRICE


May 7, 2021 (Close)

TRACK NEULAND LABS

  • Track your investment in NEULAND LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NEULAND LABS

NEULAND LABS 5-YR ANALYSIS

COMPARE NEULAND LABS WITH

FEATURED VIDEOS

The 'Big' Money is in this 'Small' Detail

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

It's a Great Time to Buy Gold

More Featured Videos

MARKET STATS